Summary
Eli Lilly and Company (LLY) announced on January 31, 2022, its intention to redeem all outstanding €600,000,000 of its 1.000% Notes due 2022. The redemption is scheduled to occur on March 2, 2022. This action represents a proactive financial management strategy by Lilly, likely aimed at optimizing its capital structure or reducing interest expenses.
Key Highlights
- 1Eli Lilly is redeeming its €600 million 1.000% Notes due 2022.
- 2The redemption date is set for March 2, 2022.
- 3The redemption price will be 100% of the principal amount plus accrued interest.
- 4This indicates proactive debt management by the company.
- 5The company is taking steps to retire existing debt obligations.
Frequently Asked Questions
While the filing doesn't state a specific reason, companies typically redeem debt early to reduce interest expenses, take advantage of lower prevailing interest rates, or to simplify their capital structure. This move suggests Lilly's management sees a financial benefit in paying off this debt early.
The redemption price is set at 100% of the principal amount (€600 million) plus any accrued and unpaid interest up to the redemption date of March 2, 2022. The exact interest amount will depend on the precise number of days from the last interest payment date to March 2, 2022.
This redemption will reduce Eli Lilly's outstanding debt by €600 million and will result in an outflow of cash equal to the redemption price. It will also reduce the company's future interest expense. The net impact on profitability will depend on the cost of this early repayment versus the interest savings.
Yes, investors holding the 1.000% Notes due 2022 will receive their principal back plus accrued interest on March 2, 2022, instead of holding the notes until their original maturity date. They will no longer receive future interest payments from these specific notes.